Report scope. This 2026 Drug Asset Due Diligence Report evaluates Talabostat Mesylate as a potential licensing, partnership, acquisition, or option asset. The review separates verified evidence from open diligence questions across clinical development, intellectual property, market positioning, and transaction precedent.
Executive recommendation: CONDITIONAL GO
Talabostat Mesylate is a Small molecule drug associated with DPP-4 x DPP-8 x DPP-9 x DPP2 x FAP and a global highest development stage of Phase 2. The lead disclosed indication is Metastatic Pancreatic Ductal Adenocarcinoma. The current evidence supports a CONDITIONAL GO posture, subject to confirmation of study-level data, ownership, patent coverage, manufacturing readiness, and regional rights.
Decision memo
- Asset: Talabostat Mesylate
- Target: DPP-4 x DPP-8 x DPP-9 x DPP2 x FAP
- Lead indication: Metastatic Pancreatic Ductal Adenocarcinoma
- Highest phase: Phase 2
- Matched trials: 14
- Matched result records: 13
- Matched asset deals: 1
Use PatSnap Life Sciences MCP servers to validate the Talabostat Mesylate diligence evidence.
1. Asset identity and development status
The first diligence task is entity resolution. Teams should reconcile development codes, nonproprietary names, salts, formulations, combinations, sponsors, and predecessor owners before relying on portfolio counts. For Talabostat Mesylate, the MCP profile identifies DPP-4 x DPP-8 x DPP-9 x DPP2 x FAP as the primary target context and Metastatic Pancreatic Ductal Adenocarcinoma as the lead indication. Global phase labels are useful orientation points, but investment decisions require country- and indication-level status verification.
Confirm the exact molecule, formulation, route, dose, biomarker definition, and current sponsor. Review discontinuations separately from active development so that an historical high phase is not mistaken for a live program.
Use PatSnap Life Sciences MCP servers to validate the Talabostat Mesylate diligence evidence.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT05703542 | Phase 1 | Recruiting | Not disclosed | Not disclosed |
| NCT05558982 | Phase 2 | Active, not recruiting | Not disclosed | Not disclosed |
| NCT04171219 | Phase 2 | Terminated | Not disclosed | Not disclosed |
| NCT04123574 | Early Phase 1 | Withdrawn | Not disclosed | Not disclosed |
| NCT03910660 | Phase 1/2 | Completed | Not disclosed | Not disclosed |
| NCT00489710 | Phase 2 | Withdrawn | Not disclosed | Not disclosed |
| NCT00303940 | Phase 1 | Completed | Not disclosed | Not disclosed |
| NCT00290017 | Phase 3 | Terminated | Not disclosed | Not disclosed |
| NCT00243204 | Phase 3 | Terminated | Not disclosed | Not disclosed |
| NCT00116389 | Phase 2 | Terminated | Not disclosed | Not disclosed |
| NCT00086203 | Phase 2 | Completed | Not disclosed | Not disclosed |
| NCT00083239 | Phase 2 | Completed | Not disclosed | Not disclosed |
| NCT00083252 | Phase 2 | Completed | Not disclosed | Not disclosed |
| NCT00080080 | Phase 2 | Completed | Not disclosed | Not disclosed |
The clinical program should be audited for randomization, comparator relevance, dose selection, endpoint hierarchy, multiplicity, analysis population, geographic mix, and readout timing. Early-stage programs require attention to pharmacokinetics, pharmacodynamics, adverse events, dose-limiting toxicities, and the rationale for the expansion dose.
Use PatSnap Life Sciences MCP servers to validate the Talabostat Mesylate diligence evidence.
3. Clinical readouts: what is known
BXCL701 plus pembrolizumab in second-line advanced pancreatic ductal adenocarcinoma: Final outcomes of the EXPEL PANC trial.
Study: NCT05558982 (EXPEL PANC, ASCO2026). Phase: Phase 2. Enrollment: 21. Published: 2026-05-29.
PFS(18-week) = 22.0 %
A Phase 2 Basket Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases (DPP), Administered in Combination With Pembrolizumab in Patients With Advanced Solid Cancers
Study: NCT04171219 (CTgov). Phase: Phase 2. Enrollment: 31. Published: 2025-05-16.
Disease Control Rate Per RECIST v1.1 = 4 Pts | Disease Control Rate Per RECIST v1.1 = 4 Pts
1622P - A phase II study of the first-in-class oral innate immune activator BXCL701 with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC): Long-term follow-up
Study: NCT03910660 (ESMO2024). Phase: Phase 2. Enrollment: 29. Published: 2024-09-15.
CRR = 21 %
Phase II trial of BXCL701 and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (EXPEL-PANC): Preliminary findings.
Study: NCT05558982 (EXPEL-PANC, ASCO2024). Phase: Phase 2. Enrollment: 6. Published: 2024-06-02.
PFS(18-week) = 1 Pts
BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) of Adenocarcinoma Phenotype
Study: NCT03910660 (Biospace). Phase: Phase 2. Enrollment: 29. Published: 2023-11-08.
mOS = 15.5 Month (95%CI, 9.6 - NR)
BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Small Cell Neuroendocrine Prostate Cancer
Study: NCT03910660 (GlobeNewswire). Phase: Phase 2. Enrollment: 34. Published: 2023-10-11.
ORR = 20 %
First-in-class oral innate immune activator BXCL701 combined with pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC) of small cell neuroendocrine (SCNC) phenotype: Phase 2a final results.
Study: NCT03910660 (ASCO_GU2023). Phase: Phase 2. Enrollment: 27. Published: 2023-02-21.
Composite Response = 5 Pts
BXCL701: First-in-class oral activator of systemic innate immunity combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of small-cell neuroendocrine carcinoma (SCNC) phenotype—Phase 2a interim results.
Study: NCT03910660 (ASCO_GU2022). Phase: Phase 2. Enrollment: 16. Published: 2022-02-16.
Composite Response = 30 %
BXCL701: First-in-class oral activator of systemic innate immunity combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of adenocarcinoma phenotype—Phase 2a results.
Study: NCT03910660 (ASCO_GU2022). Phase: Phase 2. Enrollment: 40. Published: 2022-02-16.
CTC conversion = 25 %
Targeting innate immunity with BXCL701 in combination with pembrolizumab in patients with advanced solid cancers: Phase 2 basket study.
Study: NCT04171219 (ASCO 12021 | ASCO 22021). Phase: Phase 2. Enrollment: 16. Published: 2021-05-20.
PR = 1 Pts | PR = 1 Pts
341 Phase 1b/2 study of BXCL701, an oral activator of the systemic innate immunity pathway, combined with pembrolizumab (pembro), in men with metastatic castration-resistant prostate cancer (mCRPC)
Study: NCT03910660 (341, SITC2020). Phase: Phase 1/2. Enrollment: 13. Published: 2020-11-09.
RP2D = 0.4 mg | RP2D = 0.6 mg
Phase 2 study of talabostat/gemcitabine in Stage IV pancreatic cancer
Study: ASCO2007. Phase: Phase 2. Enrollment: 60. Published: 2007-06-20.
mPFS = 3.5 Month
Phase 2 trial of talabostat and cisplatin in patients with stage IV melanoma
Study: ASCO2006. Phase: Phase 2. Enrollment: 74. Published: 2006-06-20.
mPFS = 2.6 Month
For every reported endpoint, obtain the protocol, statistical analysis plan, patient disposition, baseline characteristics, subgroup definitions, exposure duration, and full safety tables. Conference abstracts and registry summaries can support screening, but they should not replace source data review in a binding transaction.
Use PatSnap Life Sciences MCP servers to validate the Talabostat Mesylate diligence evidence.
4. Market and competitive position
The commercial case depends on differentiated efficacy, tolerability, convenience, biomarker reach, treatment setting, and access. A target-level market may be attractive while an individual asset remains undifferentiated. Benchmark Talabostat Mesylate against approved therapies and clinical competitors in Metastatic Pancreatic Ductal Adenocarcinoma, including likely standards of care at the expected launch date.
Build a scenario model around addressable patients, diagnosis and biomarker rates, line of therapy, duration, net price, uptake, displacement, combination costs, and probability-adjusted timelines. Test slower enrollment, delayed readout, narrower labels, safety restrictions, and competitor launches.
Use PatSnap Life Sciences MCP servers to validate the Talabostat Mesylate diligence evidence.
5. Transaction precedent and economics
| Date | Transaction | Status | Type | Disclosed value |
|---|---|---|---|---|
| 2016-01-04 | BioXcel Therapeutics executed a Data Purchase Agreement with Midatech Pharma US Inc. | Active | Asset Acquisition | Not disclosed |
Transaction records should be normalized for territory, asset scope, phase at signing, option mechanics, development obligations, cost sharing, royalties, milestones, and change-of-control terms. Undisclosed economics must not be converted into invented benchmarks.
6. IP and freedom-to-operate screen
Complete a family-level patent review covering composition of matter, sequence or construct claims, polymorph and salt claims, formulation, dosing, combinations, biomarkers, manufacturing, and method of use. Verify priority, ownership, assignments, prosecution status, term adjustments, extensions, oppositions, and regional coverage. Freedom to operate is a separate legal analysis and should include competitor claims and platform dependencies.
The diligence room should reconcile inventorship, employee and contractor assignments, university or platform licenses, sublicensing restrictions, government rights, and obligations triggered by development milestones or commercialization.
Use PatSnap Life Sciences MCP servers to validate the Talabostat Mesylate diligence evidence.
7. Principal risks and diligence gates
- Identity risk: resolve all aliases, formulations, combinations, and owners.
- Clinical risk: confirm source data, protocol deviations, endpoint definitions, and safety follow-up.
- Regulatory risk: review agency correspondence, meeting minutes, holds, commitments, and indication-specific pathways.
- IP risk: validate enforceable coverage, remaining life, ownership, and freedom to operate.
- CMC risk: assess process control, analytical methods, comparability, scale-up, supply, and cost of goods.
- Commercial risk: pressure-test differentiation, market access, competitive timing, and realistic adoption.
- Transaction risk: map rights, encumbrances, royalties, options, consent requirements, and change-of-control provisions.
8. Final go/no-go memorandum
CONDITIONAL GO
Proceed only through staged diligence. Before exclusivity or a binding offer, require a verified asset identity package, complete clinical data room, regulatory correspondence, patent-family schedule, freedom-to-operate opinion, CMC package, ownership chain, regional rights map, and risk-adjusted valuation. Any material mismatch between public records and source documents should pause the process until reconciled.
Method note: This report uses PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP data retrieved on 2026-10-14. It is a screening and diligence framework, not medical, legal, regulatory, or investment advice.
